欢迎来到麦多课文档分享! | 帮助中心 海量文档,免费浏览,给你所需,享你所想!
麦多课文档分享
全部分类
  • 标准规范>
  • 教学课件>
  • 考试资料>
  • 办公文档>
  • 学术论文>
  • 行业资料>
  • 易语言源码>
  • ImageVerifierCode 换一换
    首页 麦多课文档分享 > 资源分类 > PPT文档下载
    分享到微信 分享到微博 分享到QQ空间

    How to Claim your Biotech-Based Invention.ppt

    • 资源ID:376416       资源大小:120.50KB        全文页数:20页
    • 资源格式: PPT        下载积分:2000积分
    快捷下载 游客一键下载
    账号登录下载
    微信登录下载
    二维码
    微信扫一扫登录
    下载资源需要2000积分(如需开发票,请勿充值!)
    邮箱/手机:
    温馨提示:
    如需开发票,请勿充值!快捷下载时,用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)。
    如需开发票,请勿充值!如填写123,账号就是123,密码也是123。
    支付方式: 支付宝扫码支付    微信扫码支付   
    验证码:   换一换

    加入VIP,交流精品资源
     
    账号:
    密码:
    验证码:   换一换
      忘记密码?
        
    友情提示
    2、PDF文件下载后,可能会被浏览器默认打开,此种情况可以点击浏览器菜单,保存网页到桌面,就可以正常下载了。
    3、本站不支持迅雷下载,请使用电脑自带的IE浏览器,或者360浏览器、谷歌浏览器下载即可。
    4、本站资源下载后的文档和图纸-无水印,预览文档经过压缩,下载后原文更清晰。
    5、试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。

    How to Claim your Biotech-Based Invention.ppt

    1、How to Claim your Biotech-Based Invention,Deborah Reynolds Detailee, TCPS1600 571-272-0734 Deborah.Reynoldsuspto.gov,How to Claim your Biotech-Based Invention,DNA or protein inventions (with a focus on utility) Antisense nucleic acid inventions,What is the Invention?,The famous quote from Brenner v.

    2、 Manson, 383 U.S. 519 (1966): “A patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion.”,Discovery Genetics,Expressed Sequence Tags (ESTs) Genomics Genome sequencing Bacterial Viral Mammalian Single Nucleotide Polymorphisms (SNPs) Directed

    3、 cloning,Claim Analysis,Consider the following claim:An isolated and purified nucleic acid comprising SEQ ID NO 1.,Question,What does the application disclose? Full Open Reading Frame (ORF) Application further asserts that the encoded protein is a member of a family of proteins that is already known

    4、 based upon amino acid sequence homology (i.e. comparison of entire sequence or determination of a consensus sequence).,The Protein,Two possibilities The search may support the assignment of the protein to a particular family, or may be inconclusive. The search may reveal that the protein more likel

    5、y belongs to a family other than that asserted in the application.,Example,Example: Applicant asserts that the protein is an interleukin receptor because it is 85% identical at the amino acid level with other IL-receptors. A search confirms the asserted identity and that the next closest match is a

    6、50% identity to beta-actin. No reason to doubt assertion that the protein is an IL-receptor.,Example,Utility Is there a well-established utility for IL-receptors? No. Different receptors would have different functions and the artisan would have to determine such.,Example,Is the utility specific?Mayb

    7、e. The use would be particular to a general class of receptors, but the limited amount of information present would apply equally to all IL-receptors.,Example,Is the utility substantial? No. The artisan would need to prepare, isolate, and analyze the protein in order to determine its function and us

    8、e. Therefore, the invention is not in readily available form.,Example,In the absence of an alternative utility that meets the requirements of 35 U.S.C. 101, with these facts, the claimed invention would be rejected under 35 U.S.C. 101 as failing to have patentable utility.,Example,Is there an altern

    9、ative utility? Probe? It is possible that the DNA encoding the protein would have utility as a probe. However, the probe must have a specific, substantial and credible utility under 35 U.S.C. 101.,Key Theme for Antisense Patent Examining,Structure-Function Relationships Antisense Oligo + Target Nucl

    10、eic Acid + Delivery Scheme + Cell Type + Organism = Modulation of Target and/or Therapy,“Enablement” Requirement,Commonly cited unpredictable factors for antisense: predicting target accessibility target folding/structure antisense/target protein interactions lack of correlation between in vitro and

    11、 in vivo efficient delivery to cells and cell targeting for specific disorders oligo affinity/stability in vivo “modulation” of target inhibition up-regulation in vitro (cell culture) results generally in vivo success animal model shown is not art recognized,Gene Walk Conclusions,Probability of find

    12、ing functional antisense oligo is high. A broad claim to “An isolated antisense oligonucleotide that inhibits the expression of gene X” may be enabled by providing the sequence for gene X and gene walk data (no magic number) Predictability of any single antisense being effective is low claim to spec

    13、ific antisense oligonucleotide may require evidence of function The current state of predictability for antisense may support that breadth/scope claimed is enabled but this may also raise prior art issues depending on what was known at the time of filing,Obviousness,Broad antisense claims to known g

    14、enes would be considered obvious if the prior art suggested inhibiting the gene and the gene sequence was known. The current knowledge and level of skill in the art is high such that one of ordinary skill in the art would expect at least an antisense against every known gene (i.e. at mRNA initiation

    15、 site), absent evidence to the contrary. Narrow claims to specific antisense oligos may be free of the art, when there would be no motivation to modify the prior art to achieve the specific antisense sequence claimed.,Recommendations,Claim functional antisense oligos by specific sequence. List resul

    16、ts of “gene walk” showing activity of each oligo “gene walk” data may provide a representative number of species to enable/describe a broad generic claim, but there is no magic number,Recommendations,Provide objective evidence that in vitro results are representative of in vivo applicability. Respon

    17、d to examiner-cited unpredictable factors with objective evidence to the contrary. Expert opinions are more favorably viewed when supported using objective evidence. Provide objective evidence that a particular animal model is generally accepted as representative of disease or methods of treating, particularly for humans. Objective evidence includes arguments, case law, journal articles, and experimental data and comparisons commensurate with the disclosure as filed.,Questions?,Deborah Reynolds Detailee, TCPS1600 571-272-0734 Deborah.Reynoldsuspto.gov,


    注意事项

    本文(How to Claim your Biotech-Based Invention.ppt)为本站会员(周芸)主动上传,麦多课文档分享仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知麦多课文档分享(点击联系客服),我们立即给予删除!




    关于我们 - 网站声明 - 网站地图 - 资源地图 - 友情链接 - 网站客服 - 联系我们

    copyright@ 2008-2019 麦多课文库(www.mydoc123.com)网站版权所有
    备案/许可证编号:苏ICP备17064731号-1 

    收起
    展开